Johns Hopkins opens center for psychedelic research

Moving the needle forward on psychedelic research.

Johns Hopkins opens center for psychedelic research
  • Johns Hopkins University's School of Medicine has had a psychedelic research group since 2000.
  • Funded by a $17 million donation from a number of private donors, the university will be able to open a new center.
  • This comes on the heels of an increasing acceptance of psychedelic research and use.

Johns Hopkins University's School of Medicine recently announced it'd be launching the largest psychedelics research center in the world. Its new Center for Psychedelic and Consciousness Research was funded by a $17 million donation from a group of private donors. Doctors and researchers at the center hope to learn and examine whether these psychedelic drugs will be able to treat conditions such as depression and opioid addiction.

In recent years, there has been an increased interest in psychedelic research and recreation. A number of tech entrepreneurs have jump started this once-dynamic discipline.

Paul B. Rothman, dean of the medical facility at Johns Hopkins University's School of Medicine is on record stating, "Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential."

The school has maintained a psychedelic research group since 2000, but this new initiative will allow them to conduct greater investigations and delve deeper into the psychedelic expanse.

The field has largely been a string of disconnected researchers ever since counterculture legend Timothy Leary and company began investigating the substances in the 1960s.

Progressive psychedelic research 

LSD, psilocybin, mescaline and a number of other psychedelics have been illegal in the United States for a number of decades. A small trickle of studies have come out in the intervening years showing that they may be effective medical treatments for a number of issues. This has shifted public perception considerably.

Earlier this year, Denver became one of the first cities in the United States to decriminalize magic mushrooms – the mushrooms that have psychoactive makeup of psilocybin. They did this after consulting research which suggested the compounds in mushrooms could be beneficial for treating anxiety and depression experienced by cancer patients.

A host of these psychedelic substances are still listed as Tier 1 illegal drugs in the United States, which means they're on part with much more harmful drugs like heroin and cocaine.

The new funding for this facility will help spur a five year research study to find out whether or not psilocybin can also treat alcoholism, PTSD and a few other complex mental conditions.

Primarily, they're looking to figure out the physiological effects of the drug on the brain and body. This will transfer over when it comes to treating opioid addiction and even Alzheimer's disease.

In reference to the new organization, Dr. John Krystal, chair of psychiatry at Yale University, stated, "This is an exciting initiative that brings new focus to efforts to learn about mind, brain and psychiatric disorders by studying the effects of psychedelic drugs."

The center at John Hopkins has been producing some amazing research for years. As they've explored the potential of psychedelics and other recreational drugs for psychiatric problems, they've found evidence to suggest that ketamine and its related compounds could help to treat depression.

Breaking the psychedelic taboo

The history of abuse related to psychedelics has kept a great deal of researchers at bay for years. Evidence is mounting for claims that psychedelics have a positive effect on treating a host of these mental issues, but experts are still cautious. Psychedelic treatments can't be used in a double blind experiment in the same way most drugs are tested, that is because participants will know right away whether or not they're experiencing the placebo or the real thing.

Dr. Guy Goodwin, a professor of psychiatry at Oxford mentioned the infamous Leary trials and the debacle that followed in the sixties and beyond.

"It raises the caution that the investigation of hallucinogens as treatments may be endangered by grandiose descriptions of their effects and unquestioning acceptance of their value. Timothy Leary was a research psychologist before he decided the whole world should 'Turn on, tune in, and drop out.' It is best if some steps are not retraced."

A lot has changed during that time. Messianic inklings and a cultural shift of epic proportions helped swell the psychedelic revolution of the era. If we can somehow incorporate psychedelic research in our modern institutions, we may get a second chance to do it all over again.

So far 2019 has been a banner year for psychedelic research and access. On top of Denver decriminalization, there was also the vote that decriminalized entheogenic plants in Oakland, California.

The university announced in a press release:

"The group's findings on both the promise and the risks of psilocybin helped create a path forward for its potential medical approval and reclassification from a Schedule I drug, the most restrictive federal government category, to a more appropriate level."

John Hopkins's new center will be able to continue on the research and hopefully push forth the federal government towards a more equitable and fair treatment of psychedelic use and study.

COVID-19 amplified America’s devastating health gap. Can we bridge it?

The COVID-19 pandemic is making health disparities in the United States crystal clear. It is a clarion call for health care systems to double their efforts in vulnerable communities.

Willie Mae Daniels makes melted cheese sandwiches with her granddaughter, Karyah Davis, 6, after being laid off from her job as a food service cashier at the University of Miami on March 17, 2020.

Credit: Joe Raedle/Getty Images
Sponsored by Northwell Health
  • The COVID-19 pandemic has exacerbated America's health disparities, widening the divide between the haves and have nots.
  • Studies show disparities in wealth, race, and online access have disproportionately harmed underserved U.S. communities during the pandemic.
  • To begin curing this social aliment, health systems like Northwell Health are establishing relationships of trust in these communities so that the post-COVID world looks different than the pre-COVID one.
Keep reading Show less

Decades of data suggest parenthood makes people unhappy

Decades of studies have shown parents to be less happy than their childless peers. But are the kids to blame?

(Photo by Alex Hockett / Unsplash)
Sex & Relationships
  • Folk knowledge assumes having children is the key to living a happy, meaningful life; however, empirical evidence suggests nonparents are the more cheery bunch.
  • The difference is most pronounced in countries like the United States. In countries that support pro-family policies, parents can be just as happy as their child-free peers.
  • These findings suggest that we can't rely on folk knowledge to make decisions about parenting, on either the individual or societal levels.
Keep reading Show less

Lonely? Hungry? The same part of the brain worries about both

MRI scans show that hunger and loneliness cause cravings in the same area, which suggests socialization is a need.

Credit: Dương Nhân from Pexels
Mind & Brain
  • A new study demonstrates that our brains crave social interaction with the same areas used to crave food.
  • Hungry test subjects also reported a lack of desire to socialize, proving the existence of "hanger."
  • Other studies have suggested that failure to socialize can lead to stress eating in rodents.
Keep reading Show less

A Chinese plant has evolved to hide from humans

Researchers document the first example of evolutionary changes in a plant in response to humans.

Credit: MEDIAIMAG/Adobe Stock
Surprising Science
  • A plant coveted in China for its medicinal properties has developed camouflage that makes it less likely to be spotted and pulled up from the ground.
  • In areas where the plant isn't often picked, it's bright green. In harvested areas, it's now a gray that blends into its rocky surroundings.
  • Herbalists in China have been picking the Fritillaria dealvayi plant for 2,000 years.
Keep reading Show less
Scroll down to load more…
Quantcast